What foods should I eat for Melanoma (Nutritional Support)?

Fermented foods (kefir, yogurt, kimchi, sauerkraut, miso, tempeh) — Akkermansia and Lactobacillus support; gut microbiome diversity; most critical food category during immunotherapy. High-fiber plant foods (legumes, whole grains, vegetables, fruits) — prebiotic fiber feeds Akkermansia and Faecalibacterium; 30–40g fiber/day; diverse plant foods maximize microbiome diversity. Wild-caught fatty fish (salmon, sardines, mackerel) — omega-3 EPA/DHA; reduce UV-induced DNA damage; anti-inflammatory; anti-tumor; photoprotective

What supplements help with Melanoma (Nutritional Support)?

Probiotics (100 billion CFU multi-strain) — Akkermansia muciniphila, Lactobacillus rhamnosus GG, Bifidobacterium longum, Faecalibacterium prausnitzii support; most critical supplement during immunotherapy; gut microbiome diversity predicts anti-PD-1 response. Vitamin D3 — 5,000–10,000 IU daily with K2 (200mcg MK-7); VDR expressed in melanoma cells; deficiency associated with worse prognosis; immune support; target 60–80 ng/mL. Omega-3 EPA/DHA — 3–4g daily; reduce UV-induced DNA damage; anti-inflammatory; anti-tumor; photoprotective; reduce prostaglandin E2

What are the key nutrients for Melanoma (Nutritional Support)?

Key nutrients for Melanoma (Nutritional Support) include: Probiotics, Vitamin D3, Omega-3, Astaxanthin, Selenium, Curcumin, EGCG, Resveratrol, Prebiotic fiber.

All Conditions

Cancer & Oncology Support

Melanoma (Nutritional Support)

Most dangerous skin cancer transformed by BRAF/MEK inhibitors and anti-PD-1 immunotherapy with gut microbiome diversity as the critical determinant of immunotherapy response

ProbioticsVitamin D3Omega-3AstaxanthinSeleniumCurcuminEGCGResveratrolPrebiotic fiber

Overview

Melanoma is the most dangerous skin cancer (~325,000 new cases/year globally; ~100,000 in the US) and accounts for ~75% of skin cancer deaths despite representing only 5% of skin cancer cases. Arises from melanocytes — pigment-producing cells in skin, eyes, and mucous membranes. BRAF V600E mutation in ~50% of cutaneous melanoma; BRAF V600K in ~10%; NRAS mutations in ~20%; NF1 mutations in ~15%. Five-year survival: ~99% (stage I), ~65% (stage III), ~25% (stage IV — dramatically improved with modern therapy). Treatments: wide local excision (WLE) with sentinel lymph node biopsy, BRAF/MEK inhibitors (dabrafenib + trametinib, vemurafenib + cobimetinib, encorafenib + binimetinib — COLUMBUS trial: 58.4% ORR), immunotherapy (pembrolizumab — KEYNOTE-006; nivolumab — CheckMate 066/067; ipilimumab — anti-CTLA-4; nivolumab + ipilimumab — CheckMate 067: 5-year OS 52%), adjuvant therapy (pembrolizumab — KEYNOTE-716 for stage IIB/C; nivolumab; dabrafenib + trametinib for BRAF V600+ stage III). 2025–2026 advances: mRNA-4157/V940 (V940) + pembrolizumab — KEYNOTE-942 Phase IIb: 44% reduction in recurrence/death; FDA Breakthrough Therapy 2023; Phase III V940-001 enrolling 2024–2025; lifileucel (Amtagvi) FDA approved February 2024 — first TIL therapy approved; 31.5% ORR in heavily pretreated advanced melanoma; tebentafusp (Kimmtrak) FDA approved January 2022 for HLA-A*02:01+ uveal melanoma — first TCR bispecific approved; 9.9-month OS vs 6.3 months; fianlimab (anti-LAG-3) + cemiplimab — RELATIVITY-098 Phase III vs pembrolizumab first-line (results expected 2025); pembrolizumab + lenvatinib (LEAP-004): 21.4% ORR in PD-1-refractory advanced melanoma; nivolumab + relatlimab adjuvant arm in trials; anti-TIGIT and anti-TIM-3 combinations in Phase II/III; BRAF/MEK + anti-PD-1 triple combinations (spartalizumab + dabrafenib + trametinib — COMBI-i). Nutritional rationale: gut microbiome diversity is the strongest nutritional determinant of immunotherapy response — Akkermansia muciniphila, Faecalibacterium prausnitzii, and Bifidobacterium longum associated with better anti-PD-1 response; vitamin D and melanoma prognosis (inverse association — vitamin D receptor expressed in melanoma cells); omega-3 and UV-induced DNA damage protection; antioxidants and photoprotection.

Evidence highlight: Lifileucel (Amtagvi) FDA approved February 2024 — first TIL therapy; 31.5% ORR in heavily pretreated advanced melanoma (Chesney et al., 2023). Tebentafusp FDA approved January 2022 for uveal melanoma — first TCR bispecific; 9.9-month OS vs 6.3 months (Nathan et al., 2021). mRNA-4157/V940 + pembrolizumab: 44% reduction in recurrence/death in KEYNOTE-942 Phase IIb (Khattak et al., 2023); Phase III enrolling 2024–2025. Relatlimab + nivolumab (Opdualag) FDA approved 2022 — RELATIVITY-047: 10.1-month PFS vs 4.6 months (Tawbi et al., 2022). LEAP-004: pembrolizumab + lenvatinib 21.4% ORR in PD-1-refractory melanoma (Arance et al., 2023). Gut microbiome diversity predicts anti-PD-1 response — Akkermansia muciniphila associated with better response (Routy et al., 2018; Gopalakrishnan et al., 2018). Antibiotic use before immunotherapy associated with worse OS in melanoma (Derosa et al., 2018).

Core Nutrition Principles

1Gut microbiome diversity is the most critical nutritional factor for immunotherapy response — Akkermansia muciniphila, Faecalibacterium prausnitzii, and Bifidobacterium longum associated with better anti-PD-1/CTLA-4 response; high-fiber diet and fermented foods are essential during immunotherapy
2Vitamin D deficiency is strongly associated with worse melanoma prognosis — vitamin D receptor (VDR) is expressed in melanoma cells; supplementation supports immune surveillance and anti-tumor immunity
3Omega-3 EPA/DHA reduce UV-induced DNA damage, prostaglandin E2, and tumor-promoting inflammation — photoprotective and anti-tumor mechanisms
4Selenium (food sources) associated with reduced melanoma risk — selenomethionine from Brazil nuts and seafood; antioxidant and DNA repair mechanisms
5Astaxanthin is the most potent carotenoid antioxidant — photoprotective; reduces UV-induced oxidative DNA damage; anti-inflammatory; anti-tumor in melanoma cell lines
6Polyphenols (resveratrol, EGCG, curcumin) inhibit melanoma cell proliferation and invasion — anti-tumor, anti-angiogenic, and anti-metastatic mechanisms
7Antibiotic use before immunotherapy significantly impairs response — antibiotics devastate gut microbiome; avoid unnecessary antibiotics; if required, aggressive probiotic and prebiotic restoration is essential
8High-fiber diet (30–40g/day) is the most evidence-based dietary intervention for gut microbiome diversity and immunotherapy response — diverse plant foods, legumes, whole grains

Priority Foods

Fermented foods (kefir, yogurt, kimchi, sauerkraut, miso, tempeh) — Akkermansia and Lactobacillus support; gut microbiome diversity; most critical food category during immunotherapy
High-fiber plant foods (legumes, whole grains, vegetables, fruits) — prebiotic fiber feeds Akkermansia and Faecalibacterium; 30–40g fiber/day; diverse plant foods maximize microbiome diversity
Wild-caught fatty fish (salmon, sardines, mackerel) — omega-3 EPA/DHA; reduce UV-induced DNA damage; anti-inflammatory; anti-tumor; photoprotective
Cooked tomatoes and tomato paste — lycopene; photoprotective; antioxidant; anti-tumor; cooking increases lycopene bioavailability
Brazil nuts (2/day) — selenium (200mcg); antioxidant; DNA repair; associated with reduced melanoma risk
Green tea (3–5 cups/day) — EGCG; anti-tumor in melanoma cell lines; anti-angiogenic; antioxidant; photoprotective
Berries (blueberries, raspberries, blackberries) — anthocyanins; antioxidants; anti-tumor; anti-inflammatory; gut microbiome support
Turmeric with black pepper and fat — curcumin; anti-tumor in melanoma cell lines; NF-kB inhibition; anti-angiogenic; anti-metastatic
Cruciferous vegetables (broccoli, cauliflower, Brussels sprouts) — sulforaphane; anti-tumor; NRF2 activation; gut microbiome support
Pomegranate — ellagic acid; anti-tumor; anti-angiogenic; anti-metastatic in melanoma cell lines
Dark chocolate (>85% cacao) — flavonoids; antioxidants; gut microbiome support; anti-inflammatory

Core Supplements

Probiotics (100 billion CFU multi-strain) — Akkermansia muciniphila, Lactobacillus rhamnosus GG, Bifidobacterium longum, Faecalibacterium prausnitzii support; most critical supplement during immunotherapy; gut microbiome diversity predicts anti-PD-1 response
Vitamin D3 — 5,000–10,000 IU daily with K2 (200mcg MK-7); VDR expressed in melanoma cells; deficiency associated with worse prognosis; immune support; target 60–80 ng/mL
Omega-3 EPA/DHA — 3–4g daily; reduce UV-induced DNA damage; anti-inflammatory; anti-tumor; photoprotective; reduce prostaglandin E2
Astaxanthin — 12–24mg daily; most potent carotenoid antioxidant; photoprotective; reduces UV-induced oxidative DNA damage; anti-tumor in melanoma cell lines; anti-inflammatory
Selenium (selenomethionine) — 200mcg daily; antioxidant; DNA repair; associated with reduced melanoma risk; immune support; do not exceed 400mcg/day
Curcumin (liposomal or phytosome) — 1,000–2,000mg daily; anti-tumor in melanoma cell lines; NF-kB inhibition; anti-angiogenic; anti-metastatic; anti-inflammatory
Green tea extract (EGCG) — 400–800mg daily standardized to 45% EGCG; anti-tumor; anti-angiogenic; antioxidant; photoprotective
Resveratrol — 250–500mg daily; anti-tumor in melanoma cell lines; SIRT1 activation; anti-angiogenic; anti-metastatic; take with fat for absorption
Prebiotic fiber (inulin, FOS, psyllium) — 10–20g daily; feed Akkermansia and Bifidobacterium; gut microbiome diversity; immunotherapy response
Vitamin C (liposomal) — 2,000–4,000mg daily; antioxidant; immune support; collagen synthesis for wound healing post-surgery; photoprotective
Melatonin — 10–20mg at bedtime; anti-tumor; antioxidant; improves sleep; discuss with oncologist during active immunotherapy
Zinc picolinate — 30mg daily; DNA repair; immune function; wound healing post-surgery; antioxidant

Treatment Protocols

Wide local excision (WLE) — primary treatment; margins based on Breslow thickness (1mm for T1, 1–2cm for T2–T4); sentinel lymph node biopsy for tumors >0.8mm
Complete lymph node dissection (CLND) — for positive sentinel lymph node; MSLT-II trial showed no OS benefit vs observation alone; now used selectively
Pembrolizumab (KEYNOTE-006) — first-line for advanced melanoma; 33% ORR; 5-year OS 38%; FDA approved 2014; preferred for PD-L1+ tumors
Nivolumab + ipilimumab (CheckMate 067) — first-line combination; 5-year OS 52%; 58% ORR; FDA approved 2015; highest efficacy but significant toxicity (immune-related AEs in 59%)
Relatlimab + nivolumab (Opdualag) — anti-LAG-3 + anti-PD-1; FDA approved March 2022; RELATIVITY-047: 10.1-month PFS vs 4.6 months with nivolumab alone; 43% ORR; first LAG-3 inhibitor approved
Dabrafenib + trametinib — BRAF V600E/K + MEK inhibitor; FDA approved for BRAF V600+ advanced melanoma; 69% ORR; COMBI-d/v trials; preferred for rapid disease control in high tumor burden
Encorafenib + binimetinib (COLUMBUS) — BRAF + MEK inhibitor; 58.4% ORR; 14.9-month PFS; FDA approved 2018; favorable tolerability profile
Lifileucel (Amtagvi) — TIL (tumor-infiltrating lymphocyte) therapy; FDA approved February 2024 for advanced melanoma; 31.5% ORR in heavily pretreated patients; first TIL therapy approved; requires lymphodepletion and IL-2
mRNA-4157/V940 (V940) + pembrolizumab — personalized neoantigen mRNA vaccine; KEYNOTE-942 Phase IIb: 44% reduction in recurrence/death vs pembrolizumab alone in resected high-risk melanoma; FDA Breakthrough Therapy 2023; Phase III V940-001 enrolling 2024–2025; most promising cancer vaccine platform in decades
Tebentafusp (Kimmtrak) — TCR bispecific T-cell engager targeting gp100/HLA-A*02:01; FDA approved January 2022 for HLA-A*02:01+ unresectable/metastatic uveal melanoma; 9.9-month OS vs 6.3 months; first approved therapy for uveal melanoma; first approved TCR bispecific antibody
Fianlimab + cemiplimab — anti-LAG-3 + anti-PD-1 combination; RELATIVITY-098 Phase III vs pembrolizumab first-line (results expected 2025); potentially superior to relatlimab + nivolumab (Opdualag)
Pembrolizumab + lenvatinib (LEAP-004) — for PD-1-refractory advanced melanoma; 21.4% ORR; 6.3-month PFS; option after anti-PD-1 progression; FDA approved for this indication
Adjuvant pembrolizumab (KEYNOTE-716) — for resected stage IIB/C melanoma; 12-month RFS 90.4% vs 83.2%; FDA approved 2021
Adjuvant nivolumab or dabrafenib + trametinib — for resected stage III melanoma; FDA approved; choice based on BRAF status
UV protection — SPF 50+ broad-spectrum sunscreen daily; UPF 50+ clothing; avoid tanning beds; seek shade 10am–4pm; most important prevention strategy
Gut microbiome optimization before immunotherapy — high-fiber diet, fermented foods, probiotics; avoid antibiotics; fecal microbiota transplant (FMT) from immunotherapy responders in clinical trials
Dermatology surveillance — full-body skin exam every 3–6 months; dermoscopy; total body photography for high-risk patients

Foods & Substances to Avoid

UV radiation and tanning beds — primary risk factor for melanoma; UV causes direct DNA damage (cyclobutane pyrimidine dimers); tanning beds increase melanoma risk by 75%; avoid completely
Antibiotics before or during immunotherapy — devastate gut microbiome; significantly impair anti-PD-1 response; associated with worse immunotherapy outcomes in multiple studies; avoid unless absolutely necessary
Low-fiber, processed Western diet — impairs gut microbiome diversity; reduces Akkermansia and Faecalibacterium; worsens immunotherapy response; most important dietary pattern to avoid during immunotherapy
Alcohol — associated with increased melanoma risk; impairs gut microbiome diversity; worsens immunotherapy response; hepatotoxic during BRAF/MEK inhibitor therapy
High-dose antioxidants during active immunotherapy (controversial) — may reduce immunotherapy efficacy by reducing reactive oxygen species needed for T-cell killing; discuss with oncologist; vitamin D, omega-3, and probiotics are exceptions
Grapefruit with dabrafenib, trametinib, encorafenib, or binimetinib — CYP3A4 inhibition significantly increases drug levels and toxicity
St. John's Wort — CYP3A4 inducer; reduces BRAF/MEK inhibitor efficacy
Proton pump inhibitors (PPIs) — impair gut microbiome diversity; associated with worse immunotherapy response in multiple studies; use only when medically necessary
Processed foods and refined sugar — pro-inflammatory; impair gut microbiome diversity; worsen immunotherapy response

Get your personalized protocol

Take the full assessment to receive a protocol tailored to your specific symptoms and goals.

Start Assessment

Key Nutrients

ProbioticsVitamin D3Omega-3AstaxanthinSeleniumCurcuminEGCGResveratrolPrebiotic fiber

Drug & Supplement Interactions

Some nutrients in this protocol may interact with medications. Always inform your prescriber of all supplements you take.

Vitamin KSignificant

•Warfarin (Coumadin) — vitamin K directly antagonizes warfarin; any change in intake requires INR monitoring
•Other anticoagulants (rivaroxaban, apixaban) — consult prescriber before supplementing
•Antibiotics — broad-spectrum antibiotics reduce gut bacteria that produce vitamin K2

Vitamin K2Significant

•Warfarin (Coumadin) — directly antagonizes anticoagulant effect; requires INR monitoring
•Other anticoagulants — consult prescriber; even small changes in K2 intake affect INR

Vitamin AModerate

•Retinoids (isotretinoin, tretinoin) — additive toxicity risk; do not combine
•Warfarin — high-dose vitamin A may increase anticoagulant effect
•Orlistat — reduces fat-soluble vitamin absorption including vitamin A
•Cholestyramine — reduces vitamin A absorption

Vitamin B6Moderate

•Levodopa — B6 reduces drug effectiveness; avoid unless combined with carbidopa
•Phenytoin and phenobarbital — B6 may reduce drug levels

Vitamin B3Moderate

•Statins — combination increases risk of myopathy; use with caution
•Diabetes medications — high-dose niacin may impair glucose control
•Blood pressure medications — additive vasodilatory effect

ProbioticsCaution

•Immunosuppressants — use with caution; risk of infection in severely immunocompromised patients
•Antibiotics — take probiotics 2+ hours away from antibiotics to preserve viability
•Antifungals — may reduce probiotic viability

Vitamin DCaution

•Thiazide diuretics — combined with high-dose vitamin D may cause hypercalcemia
•Digoxin — hypercalcemia from excess vitamin D increases digoxin toxicity risk
•Corticosteroids — long-term use depletes vitamin D; supplementation is recommended
•Orlistat (weight loss drug) — reduces vitamin D absorption by up to 30%
•Cholestyramine — reduces vitamin D absorption; separate by 4+ hours
•Phenobarbital and phenytoin — accelerate vitamin D metabolism; may require higher doses

Vitamin ECaution

•Blood thinners (warfarin, aspirin) — additive antiplatelet effect at doses >400 IU/day
•Chemotherapy and radiation — high-dose vitamin E may reduce treatment effectiveness; consult oncologist
•Statins — may reduce statin effectiveness at very high doses
•Cyclosporine — may reduce drug levels
•Niacin — high-dose combination may reduce HDL-raising effect of niacin

Vitamin CCaution

•Warfarin — high doses (>1g/day) may reduce anticoagulant effect
•Chemotherapy — high-dose IV vitamin C may interact with certain agents; consult oncologist
•Iron supplements — significantly enhances iron absorption (beneficial in deficiency, caution in hemochromatosis)
•Statins — very high doses may reduce statin effectiveness
•Aluminum antacids — vitamin C increases aluminum absorption; avoid combination

Vitamin B12Caution

•Metformin — long-term use depletes B12; supplementation is recommended
•PPIs and H2 blockers — reduce B12 absorption; supplementation recommended with long-term use
•Chloramphenicol — may reduce B12 effectiveness

Omega-3Caution

•Blood thinners (warfarin, clopidogrel, aspirin) — additive antiplatelet effect; monitor INR at doses >2g/day
•Blood pressure medications — additive hypotensive effect at high doses (>3g/day)
•Cyclosporine — may reduce drug levels; monitor in transplant patients

AstaxanthinCaution

•Blood thinners — mild antiplatelet effect
•Blood pressure medications — additive hypotensive effect
•Diabetes medications — may enhance blood-glucose-lowering effect

SeleniumCaution

•Chemotherapy (cisplatin) — may reduce drug effectiveness; consult oncologist
•Anticoagulants — high doses may have mild antiplatelet effect
•Statins — may interact with statin metabolism at high doses

CurcuminCaution

•Blood thinners (warfarin, aspirin, clopidogrel) — additive antiplatelet effect at high doses
•Diabetes medications — may enhance blood-glucose-lowering effect
•Chemotherapy drugs — may interact with certain agents; consult oncologist
•Acid-reducing medications (PPIs, H2 blockers) — curcumin may reduce stomach acid
•Iron — may reduce iron absorption

EGCGCaution

•Blood thinners — mild antiplatelet effect
•Iron — significantly reduces iron absorption; separate by 2+ hours
•Bortezomib (chemotherapy) — EGCG may reduce drug effectiveness
•Stimulants — green tea EGCG contains caffeine; additive stimulant effect

ResveratrolCaution

•Blood thinners (warfarin, aspirin) — additive antiplatelet effect
•Estrogen-sensitive conditions — resveratrol has weak estrogenic activity
•CYP450 substrates — resveratrol inhibits CYP3A4 and CYP2C9; may increase levels of many medications
•Chemotherapy — may interact with some agents; consult oncologist

FiberCaution

•Oral medications — high fiber intake may slow or reduce drug absorption; separate by 1–2 hours
•Diabetes medications — fiber slows glucose absorption; may enhance blood-glucose-lowering effect

This list covers common interactions and is not exhaustive. Consult a pharmacist or physician before combining supplements with prescription medications.